Already in 1998, trastuzumab(Herceptin), a monoclonal antibody specific for cancer cells that produce excessive oncoprotein HER2 (human epidermal growth factor receptor 2, also known as ErbB2), was approved in the treatment of metastatic breast cancer [64] (Table 1). This evidence concerns the gene ERBB2 and cancer.